Immunomodulation: The future of allergy and asthma treatment

R. Matthew Bloebaum, J. Andrew Grant, Sanjiv Sur

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose of review: As the prevalence of asthma and allergic disease increases around the world, it is clear that more effective therapies and disease-modifying agents are needed. Treatment for allergic disease is evolving with an increase in understanding of the etiology. Recent findings: The first immunomodulatory treatment was recently approved for use in the United States when the Food and Drug Administration approved the use of a humanized monoclonal anti-IgE antibody in patients with allergic asthma. Another strategy that has proved effective in a murine model is the downregulation of the whole immune system by targeting adhesion molecules, which has been evaluated in a recent human trial. Other strategies for the treatment of allergic diseases concentrate on refocusing the immune system away from an allergic-type response. These include the use of targeted therapies towards specific cytokines, cytokine receptors or chemokine receptors, and the use of specific bacterial DNA sequences (unmethylated cytosine-guanine dinucleotides). Finally, attention is being focused on possible therapies that may tilt the immune response to a non-allergic response by interfering with signaling molecule pathways. Summary: Immunomodulation will play a key role in future therapies for allergic disease. These treatment modalities may not only treat allergic disease, but also be beneficial in reducing the morbidity and mortality for which it is responsible.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume4
Issue number1
DOIs
StatePublished - Feb 2004

Fingerprint

Immunomodulation
Hypersensitivity
Asthma
Therapeutics
Immune System
Bacterial DNA
Cytokine Receptors
Chemokine Receptors
United States Food and Drug Administration
Down-Regulation
Monoclonal Antibodies
Cytokines
Morbidity
Mortality

Keywords

  • Allergic disease
  • Asthma
  • Immunomodulation
  • T helper type 2 cytokines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunomodulation : The future of allergy and asthma treatment. / Bloebaum, R. Matthew; Grant, J. Andrew; Sur, Sanjiv.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 4, No. 1, 02.2004, p. 63-67.

Research output: Contribution to journalArticle

Bloebaum, R. Matthew ; Grant, J. Andrew ; Sur, Sanjiv. / Immunomodulation : The future of allergy and asthma treatment. In: Current Opinion in Allergy and Clinical Immunology. 2004 ; Vol. 4, No. 1. pp. 63-67.
@article{b364fb3a3d6449c7880aef7280a88f5c,
title = "Immunomodulation: The future of allergy and asthma treatment",
abstract = "Purpose of review: As the prevalence of asthma and allergic disease increases around the world, it is clear that more effective therapies and disease-modifying agents are needed. Treatment for allergic disease is evolving with an increase in understanding of the etiology. Recent findings: The first immunomodulatory treatment was recently approved for use in the United States when the Food and Drug Administration approved the use of a humanized monoclonal anti-IgE antibody in patients with allergic asthma. Another strategy that has proved effective in a murine model is the downregulation of the whole immune system by targeting adhesion molecules, which has been evaluated in a recent human trial. Other strategies for the treatment of allergic diseases concentrate on refocusing the immune system away from an allergic-type response. These include the use of targeted therapies towards specific cytokines, cytokine receptors or chemokine receptors, and the use of specific bacterial DNA sequences (unmethylated cytosine-guanine dinucleotides). Finally, attention is being focused on possible therapies that may tilt the immune response to a non-allergic response by interfering with signaling molecule pathways. Summary: Immunomodulation will play a key role in future therapies for allergic disease. These treatment modalities may not only treat allergic disease, but also be beneficial in reducing the morbidity and mortality for which it is responsible.",
keywords = "Allergic disease, Asthma, Immunomodulation, T helper type 2 cytokines",
author = "Bloebaum, {R. Matthew} and Grant, {J. Andrew} and Sanjiv Sur",
year = "2004",
month = "2",
doi = "10.1097/00130832-200402000-00013",
language = "English (US)",
volume = "4",
pages = "63--67",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Immunomodulation

T2 - The future of allergy and asthma treatment

AU - Bloebaum, R. Matthew

AU - Grant, J. Andrew

AU - Sur, Sanjiv

PY - 2004/2

Y1 - 2004/2

N2 - Purpose of review: As the prevalence of asthma and allergic disease increases around the world, it is clear that more effective therapies and disease-modifying agents are needed. Treatment for allergic disease is evolving with an increase in understanding of the etiology. Recent findings: The first immunomodulatory treatment was recently approved for use in the United States when the Food and Drug Administration approved the use of a humanized monoclonal anti-IgE antibody in patients with allergic asthma. Another strategy that has proved effective in a murine model is the downregulation of the whole immune system by targeting adhesion molecules, which has been evaluated in a recent human trial. Other strategies for the treatment of allergic diseases concentrate on refocusing the immune system away from an allergic-type response. These include the use of targeted therapies towards specific cytokines, cytokine receptors or chemokine receptors, and the use of specific bacterial DNA sequences (unmethylated cytosine-guanine dinucleotides). Finally, attention is being focused on possible therapies that may tilt the immune response to a non-allergic response by interfering with signaling molecule pathways. Summary: Immunomodulation will play a key role in future therapies for allergic disease. These treatment modalities may not only treat allergic disease, but also be beneficial in reducing the morbidity and mortality for which it is responsible.

AB - Purpose of review: As the prevalence of asthma and allergic disease increases around the world, it is clear that more effective therapies and disease-modifying agents are needed. Treatment for allergic disease is evolving with an increase in understanding of the etiology. Recent findings: The first immunomodulatory treatment was recently approved for use in the United States when the Food and Drug Administration approved the use of a humanized monoclonal anti-IgE antibody in patients with allergic asthma. Another strategy that has proved effective in a murine model is the downregulation of the whole immune system by targeting adhesion molecules, which has been evaluated in a recent human trial. Other strategies for the treatment of allergic diseases concentrate on refocusing the immune system away from an allergic-type response. These include the use of targeted therapies towards specific cytokines, cytokine receptors or chemokine receptors, and the use of specific bacterial DNA sequences (unmethylated cytosine-guanine dinucleotides). Finally, attention is being focused on possible therapies that may tilt the immune response to a non-allergic response by interfering with signaling molecule pathways. Summary: Immunomodulation will play a key role in future therapies for allergic disease. These treatment modalities may not only treat allergic disease, but also be beneficial in reducing the morbidity and mortality for which it is responsible.

KW - Allergic disease

KW - Asthma

KW - Immunomodulation

KW - T helper type 2 cytokines

UR - http://www.scopus.com/inward/record.url?scp=4143144096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143144096&partnerID=8YFLogxK

U2 - 10.1097/00130832-200402000-00013

DO - 10.1097/00130832-200402000-00013

M3 - Article

C2 - 15090922

AN - SCOPUS:4143144096

VL - 4

SP - 63

EP - 67

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 1

ER -